Of course, further proof is required to determine the function of novel agents in the treatment of NAFLD, such as selective PPARα modulators (fibrates, K-877), and PPARγ agonists (INT-131), PPARα/γ (DSP-8658), and PPARδ (HPP-593) [151]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.